Boston-based Ascidian Therapeutics has indicated that although nearly any gene may be editable, that capability alone does not justify pursuing every opportunity, according to the company’s Chief Financial and Business Officer, Dan Rosan. He explained that the biotech assesses partnership opportunities for its RNA exon editing platform selectively, focusing on areas where the technology could offer a distinctly improved clinical outcome rather than applying it randomly.
That standard appears to have been met by Eli Lilly, which has entered into a research partnership with Ascidian valued at up to $1.9 billion. The agreement gives Lilly the opportunity to identify and create RNA exon editing therapies aimed at genetic kidney conditions.
The partnership combines Ascidian’s RNA exon editing platform with Lilly’s expertise in genetic medicines and kidney disease. While financial details regarding the upfront payment were not disclosed, Ascidian stated that the deal could eventually total as much as $1.9 billion through upfront compensation, milestone payments tied to development and marketing, and tiered royalties on global sales.
Ascidian’s Chief Scientific Officer Robert Bell said that collaborating with Lilly provides confidence because of the pharmaceutical company’s experience in genetic medicines and its established background in renal disease research, clinical development and commercialization. Bell suggested that pairing a potentially number one therapeutic payload with a partner possessing extensive expertise could improve the chances of successfully advancing treatments to patients.
Ascidian’s RNA exon editing platform is designed to modify RNA instead of DNA by removing disease-causing exons and replacing them with healthy, or wild-type, exons inside the body. The objective is to restore normal protein production without directly altering the genome.
Rather than introducing foreign enzymes, the platform relies on the cell’s natural splicing machinery, an approach intended to reduce risks commonly associated with direct DNA modification and gene replacement strategies.
Bell explained that Ascidian has concentrated on four primary categories: genes too large to fit into a single adeno-associated virus (AAV) vector, genes with substantial mutational diversity, genes with narrow therapeutic windows and dominant diseases. where the same intervention may simultaneously reduce harmful proteins and restore healthy protein production.
Bell further noted that the technology has potential applications across a broad spectrum of both inherited and acquired diseases.
Under the kidney disease-focused collaboration, Ascidian will oversee discovery work and selected preclinical tasks, while Lilly will manage additional preclinical studies, clinical development, production, and commercialization of any resulting therapies.
According to the American Kidney Fund, kidney disease affects over 35 million people in the U.S., with inherited conditions accounting for part of this strain. The organization has also reported that researchers have identified more than 600 genetic ailments that can directly or indirectly impair kidney function.
Bell emphasized that the significant unfulfilled medical need among people living with inherited kidney diseases supports the application of advanced genetic medicine technologies such as RNA exon editing. He also suggested that many inherited kidney disorders are poorly suited for traditional gene therapy approaches because of either excessive mutation diversity or technical limitations, making them a strong fit for RNA exon editing.
Ascidian has announced a strategic collaboration with Lilly focused on developing RNA exon editing therapies for genetic kidney disorders. The agreement highlights growing interest in next-generation RNA technologies and positions Ascidian as an emerging innovator in the rapidly evolving field of genetic medicine.
The partnership combines Ascidian’s RNA exon editing platform with Lilly’s extensive development and commercialization capabilities, creating new opportunities to address inherited kidney diseases that currently have limited treatment options.
Ascidian Advances RNA Exon Editing Innovation
The collaboration represents a major milestone for Ascidian as the company continues to expand the potential applications of its RNA editing technology. Unlike traditional gene-editing approaches that permanently alter DNA, Ascidian’s platform is designed to modify RNA transcripts, potentially enabling therapeutic correction of disease-causing mutations without changing the underlying genome.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
